Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Arrowhead Pharmaceuticals (ARWR) Ownership - Who Owns Arrowhead Pharmaceuticals?
1,398 Followers
Arrowhead Pharmaceuticals (ARWR) Ownership Overview
9.12% Insiders
23.54% Mutual Funds
25.54% Other Institutional Investors
41.80% Public Companies and Individual Investors
The ownership structure of Arrowhead Pharmaceuticals (ARWR) stock is a mix of institutional, retail and individual investors. Approximately 49.08% of the company’s stock is owned by Institutional Investors, 9.12% is owned by Insiders and 41.80% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Apr 03, 2024 | James C Hamilton Chief Discovery/trans Medicine | xxxxxxxxxxxxx | $168180 |
| Mar 20, 2024 | Hongbo Lu Director | xxxxxxxxxxxxx | $82990 |
| Mar 08, 2024 | xxxxxxxxxxxxx | $1407600 | |
| Nov 22, 2023 | xxxxxxxxxxxxx | $567315 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Mar 31, 2024 | xxxxxxxxxxxxx | $228313 | |
| Mar 31, 2024 | xxxxxxxxxxxxx | $15890960 | |
| Mar 31, 2024 | xxxxxxxxxxxxx | $118375400 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 13,838,399 | Institution | 11.14% | 391,626,692 | |
| 11,533,125 | Institution | 9.29% | 326,387,438 | |
| 10,327,681 | Institution | 8.32% | 292,273,372 | |
| 4,139,000 | Institution | 3.33% | 117,133,700 | |
| 3,715,048 | Insider | 2.99% | 105,135,858 | |
| 3,552,393 | Institution | 2.86% | 100,532,722 | |
| 1,651,654 | Institution | 1.33% | 46,741,808 | |
| 1,238,919 | Institution | 1.00% | 35,061,408 | |
| 1,224,708 | Institution | 0.99% | 34,659,236 | |
| 864,014 | Institution | 0.70% | 24,451,596 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 10,327,681 | Institution | 8.32% | 292,273,372 | |
| 1,651,654 | Institution | 1.33% | 46,741,808 | |
| 1,238,919 | Institution | 1.00% | 35,061,408 | |
| 1,224,708 | Institution | 0.99% | 34,659,236 | |
| 864,014 | Institution | 0.70% | 24,451,596 | |
| 801,753 | Institution | 0.65% | 22,689,610 | |
| 795,223 | Institution | 0.64% | 22,504,811 | |
| 713,170 | Institution | 0.57% | 20,182,711 | |
| 588,110 | Institution | 0.47% | 16,643,513 | |
| 553,718 | Institution | 0.45% | 15,670,219 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,903,520 | Institution | 3.14% | 110,469,616 | |
| 3,699,482 | Institution | 2.98% | 96,149,537 | |
| 3,164,453 | Institution | 2.55% | 89,554,020 | |
| 3,364,205 | Institution | 2.71% | 79,798,943 | |
| 2,965,891 | Institution | 2.39% | 77,083,507 | |
| 1,862,827 | Institution | 1.50% | 48,414,874 | |
| 1,663,963 | Institution | 1.34% | 43,246,398 | |
| 1,505,921 | Institution | 1.21% | 41,623,656 | |
| 1,068,173 | Institution | 0.86% | 30,229,296 | |
| 991,044 | Institution | 0.80% | 28,046,545 |
FAQ
Who Owns Arrowhead Pharmaceuticals (ARWR)?
According to the latest TipRanks data, approximately 25.54% of the company's stock is held by institutional investors, 9.12% is held by insiders, and 41.80% is held by retail investors.
What percentage of Arrowhead Pharmaceuticals (ARWR) stock is held by institutional investors?
According to the latest TipRanks data, approximately 25.54% of Arrowhead Pharmaceuticals (ARWR) stock is held by institutional investors.
What percentage of Arrowhead Pharmaceuticals (ARWR) stock is held by retail investors?
According to the latest TipRanks data, approximately 41.80% of Arrowhead Pharmaceuticals (ARWR) stock is held by retail investors.
Who owns the most shares of Arrowhead Pharmaceuticals (ARWR)?
iShares owns the most shares of Arrowhead Pharmaceuticals (ARWR).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.